We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04894734
Previous Study | Return to List | Next Study

Spinal Cord Stimulation (SCS) for Spinal Cord Injury (SCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04894734
Recruitment Status : Recruiting
First Posted : May 20, 2021
Last Update Posted : February 28, 2023
Information provided by (Responsible Party):
Nandan Lad, M.D., Ph.D., Duke University

Brief Summary:

The purpose of this feasibility study is to compare the impact of Spinal cord stimulation [SCS] for Spinal Cord Injury (SCI) pain and rehabilitation. SCS, also known as Epidural Electrical Stimulation (EES), will be utilized along with conventional medical management (CMM) or CMM alone. Participation in this research study is expected to last approximately 12 months. All subjects will be evaluated and proceed with implantation of two SCS devices- one tailored based on the individual's SCI for the treatment of neuropathic pain of trunk and limb and a second near the bottom of the spinal cord (conus region) to study the impact on motor, sensory, bowel/bladder outcomes. All patients will also continue receiving CMM, such as medications and physical therapy.

Participating subjects will be randomly assigned to one of two treatment groups:

  1. Placebo arm: SCS OFF + CMM. Under the direction of the study physician, the patient may receive a variety of treatments, such as medications and various forms of rehabilitation.
  2. Treatment arm: SCS ON + CMM. The study treatment Spinal Cord Stimulation [SCS]: the study physician will perform a trial procedure to see if the study procedure works for the patient and may implant a permanent device if it is successful. There is a temporary trial procedure, or a "test drive," which usually lasts 5-7 days. If this is successful, patients will discuss a more permanent implant. This study involves the concurrent placement of two SCS devices (one focused on pain and the second for rehabilitation).

For three months, treatment group subjects will have the SCS turned on and will have rehabilitation as part of their CMM. Participants in the placebo arm will have their SCS remain off and will undergo CMM with rehabilitation therapy similar to the treatment group. Neither the subjects nor the treatment team will know which patients are in the treatment or placebo arm.

At the end of three months, the study group will be revealed and the placebo group subjects will be allowed to crossover and have their SCS turned on. Rehabilitation visits may be remote and the study duration is approximately 12 months. There may be additional blood tests and clinical exams to collect data on the effectiveness of the therapy. Data at follow-up visits will be compared to the subjects' baseline data and that of the control group at the respective visits.

Condition or disease Intervention/treatment Phase
Spinal Cord Injury at T1-T12 Level Traumatic Thoracic Spinal Cord Contusion Thoracic Spinal Cord Trauma Traumatic Thoracic Spinal Cord Laceration Post-Traumatic Thoracic Myelopathy Traumatic Thoracic Spinal Cord Myelopathy Device: EES on Device: EES off Not Applicable

Detailed Description:

This study is a prospective, single center study. Data will be collected at baseline, time of procedure (trial and permanent), trial phase, and at 1, 3, 6, 12 and 15 months post-implantation.

The primary objective of this study is to collect data on Neuromodulation to Augment Pain and Rehabilitation in Spinal Cord Injury (SCI), a real-world population while further characterizing neurophysiological measures and clinical outcomes.

The following data will be collected:

  • Baseline characteristics and demographics
  • Procedure characteristics
  • Medications
  • 10-point Numerical Rating Scales (NRS) for pain intensity Guy/Farrar Patient Global Impression of Change (PGIC) scale ASIA motor and sensory scores and impairment grade
  • QoL survey (PROMIS 29)
  • Electromyography (EMG) / Nerve Conduction Studies (NCS)
  • Spinal Cord Independence Measure (SCIM) survey
  • Ashworth spasticity scale
  • Bladder control using standard clinical urodynamic studies
  • Programming parameters and characteristics
  • Safety events (adverse events, device deficiencies, protocol deviations)

The outcome variables of interest will be collected and assessed across study visits. No pre-planned formal statistical hypothesis tests will be performed. Multivariable regression modeling and descriptive statistics will be utilized.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Feasibility of Epidural Electrical Stimulation (EES) for Improving Pain and Rehabilitation Outcomes in Patients With Spinal Cord Injury (SCI)
Actual Study Start Date : December 30, 2021
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : December 31, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: EES on
Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES on. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.
Device: EES on
Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
Other Name: SCS (Spinal Cord Stimulation)

Placebo Comparator: EES off
Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES off. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.ES off. Those in the EES off category will have their EES turned on at the 9-month timepoint.
Device: EES off
Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
Other Name: SCS

Primary Outcome Measures :
  1. Change in Multidimensional Pain Inventory (MPI)-SCI average activity score [ Time Frame: Baseline, 9 months ]
    The MPI-SCI consists of twelve 7-point subscales in three sections: (1) pain impact, (2) responses by significant others, and (3) activity. Our primary outcome is the average score of the 4 pain subscales (household activities, activities away from home, social activities, and outdoor work) for pain and consequences of SCI. These 4 scales are commonly used to create a single general activity scale. To define the degree to which pain and other consequences of injury reduced participation in a specific activity, 2 additional validated items will be used in section 3: (1) "Pain has reduced my participation in this activity," and (2) "Other consequences of SCI have reduced my participation in this activity." The response range from 0 (not at all) to 6 (extremely).

  2. Motor recovery as measured by EMG [ Time Frame: Up to 9 months ]
    EMGs will be recorded using surface or needle electrodes placed over/in the following muscles: bilateral gluteus maximus, bilateral rectus femoris, bilateral vastus lateralis, bilateral medial hamstrings, bilateral anterior tibialis and bilateral gastrocnemius. When clinically appropriate, bilateral extensor carpi radialis, bilateral biceps, and bilateral abdominal muscles will be used as controls.

  3. Motor recovery as measured by dynamometry [ Time Frame: Up to 9 months ]
    Dynamometry will be used to measure muscle force by the same blinded rater for each of the muscle groups as an additional measure of muscle contraction activity.

Secondary Outcome Measures :
  1. Change in pain as measured by 10-point Numeric Rating Scales (NRS) [ Time Frame: Baseline, 9 months ]
    Validated assessment of pain severity (0-10 scale), 0 being no pain to 10 being the worst pain, in the past 7 days.

  2. Change in Quality of Life (QOL) as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 [ Time Frame: Baseline, 9 months ]
    The PROMIS-29 is a generic health-related quality of life survey that assesses each of the 7 PROMIS domains with 4 questions. The questions are ranked on a 5-point Likert Scale. PROMIS instruments contain a fixed number of items from seven PROMIS domains: depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; and ability to participate in social roles and activities. The seven domains cover the most relevant areas of self-reported health for the greatest majority of people with chronic illness.

  3. Change in the number of prescriptions written as measured by Electronic Health Record abstraction. [ Time Frame: Baseline, 9 months ]
  4. Change in the number of opioid prescriptions filled as measured by Electronic Health Record abstraction. [ Time Frame: Baseline, 9 months ]
  5. Change in the overall improvement as measured by Guy/Farrar Patient Global Impression of Change (PGIC) scale [ Time Frame: Baseline, 9 months ]
    The self-report measure PGIC reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement.

  6. Change in motor recovery as measured by the Total American Spinal Injury Association (ASIA) motor score [ Time Frame: Baseline, 9 months ]
    ASIA Upper Extremity and Lower Extremity Motor Score (UEMS & LEMS), combine to give Total ASIA Motor Score.

  7. Change in motor recovery as measured by the ASIA impairment grades [ Time Frame: Baseline, 9 months ]
    The ASIA Impairment Scale (AIS), based on the Frankel scale, is a clinician-administered scale used to classify the severity (completeness) of injury in individuals with SCI. It identifies sensory and motor levels indicative of the highest spinal level demonstrating "unimpaired" function. Preservation of function in the sacral segments (S4-S5) is a key for determining the AIS grade. AIS scores are considered essential when classifying persons with SCI as to their neurological status.

  8. Change in independence of activities of daily living (ADLs) as measured by the Spinal Cord Independence Measure (SCIM) survey [ Time Frame: Baseline, 9 months ]
    SCIM Disability scale developed to specifically address the ability of SCI patients to perform basic activities of daily living independently. Three versions of the SCIM (I-III) have been consecutively developed and assess three areas: 1) self-care (feeding, grooming, bathing, and dressing); 2) respiration and sphincter management; 3) mobility (bed and transfers and indoor/outdoor). The item scores are weighted related to the assumed clinical relevance.

  9. Change in limb movement as measured by the Ashworth spasticity scale [ Time Frame: Baseline, 9 months ]
    The Ashworth scale is the most widely used assessment tool to measure resistance to limb movement in a clinic setting, although it is unable to distinguish between the neural and non-neural components of increased tone.

  10. Change in bladder control using urodynamics [ Time Frame: Baseline, 9 months ]
    A urodynamic test is used to measure nerve and muscle function, pressure around and in the bladder, flow rates, and other factors. These tests look at how well the bladder, sphincters, and urethra are storing and releasing urine. All measures are combined to give one overall score of bladder control.

  11. Change in motor recovery as measured by Transcranial Magnetic Stimulation Motor Evoked Potentials (TMS MEPs) [ Time Frame: Baseline, 9 months ]
    To evaluate the connectivity of descending motor signals passing through the injury, TMS MEPs are recorded bilaterally over the rectus femoris (RF), vastus lateralis (VL), medial hamstring (MH), tibialis anterior (TA), medial gastrocnemius (MG), and soleus (SOL) muscles using skin surface EMG at a sampling rate of 4 kHz.

  12. Change in sensory recovery as measured by Somatosensory Evoked Potentials (SSEPs) [ Time Frame: Baseline, 9 months ]
    SSEPs will be recorded over the scalp and lumbar spine region to detect ascending sensory signals across the injury. To test for the presence of a dis-complete SCI profile, the subject was positioned supine, and while EES was off, he attempted to maximally contract muscles both above and below the injury with intention focused on increasing motor activity in either the left or right leg.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects enrolled in this study must meet all of the following inclusion criteria (based on investigator judgement):

  1. Traumatic, thoracic SCI
  2. Chronic pain (i.e., Pain >3 for > 3 months)
  3. Willing and able to provide informed consent, attend required study visits, and complete required assessments/questionnaires
  4. 18-80 years of age
  5. Medically stable enough to undergo surgical implantation of an SCS / participate in rehabilitation regimens

Exclusion Criteria:

Subjects enrolled in this study must not meet any of the following exclusion criteria (based on investigator judgement):

  1. Complete cord transection
  2. Persistent spinal instability or other injury preventing ability to participate
  3. Active infection
  4. Comorbid psychosis or psychotic disorder
  5. Untreated, clinically significant depression
  6. Active drug or alcohol abuse
  7. Pregnant women or women who intend to become pregnant during the duration of the study. Women of childbearing potential need a negative pregnancy test

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04894734

Layout table for location contacts
Contact: Allison Spell 919-681-4937 allison.spell@duke.edu
Contact: Beth Perry, RN 919-681-2695 beth.perry@duke.edu

Layout table for location information
United States, North Carolina
Duke University Health Systems Recruiting
Durham, North Carolina, United States, 27710
Contact: Allison Spell    919-681-4937    allison.spell@duke.edu   
Sponsors and Collaborators
Nandan Lad, M.D., Ph.D.
Layout table for investigator information
Principal Investigator: Shivanand Lad, MD, PhD Duke University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Nandan Lad, M.D., Ph.D., Professor of Neurosurgery, Duke University
ClinicalTrials.gov Identifier: NCT04894734    
Other Study ID Numbers: Pro00106738
First Posted: May 20, 2021    Key Record Dates
Last Update Posted: February 28, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Nandan Lad, M.D., Ph.D., Duke University:
Spinal Cord Injury
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Cord Injuries
Spinal Cord Diseases
Bone Marrow Diseases
Wounds and Injuries
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Hematologic Diseases
Wounds, Nonpenetrating